PharmaEngine (4162) reported revenue of NT$22.5 million for Oct 2026, -18.3% year on year and -89.9% from the previous month. Revenue for Jan–Oct 2026 was NT$787.8 million (+20.5% year on year).
In Oct 2026, it ranked No. 121 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$22.5 million | -18.3% | -89.9% |
| Sep 2026 | NT$223.4 million | +13.1% | +982.1% |
| Aug 2026 | NT$20.6 million | -7.0% | -11.5% |
| Jul 2026 | NT$23.3 million | +4.4% | -88.7% |
| Jun 2026 | NT$205.9 million | +33.9% | +631.2% |
| May 2026 | NT$28.2 million | +51.9% | +17.3% |
| Apr 2026 | NT$24 million | -2.1% | -84.5% |
| Mar 2026 | NT$154.5 million | +6.0% | +1,080.9% |
| Feb 2026 | NT$13.1 million | -28.1% | -81.9% |
| Jan 2026 | NT$72.2 million | +208.3% | -68.3% |
| Dec 2025 | NT$227.5 million | -87.6% | +657.6% |
| Nov 2025 | NT$30 million | +29.9% | +8.9% |
| Oct 2025 | NT$27.6 million | +24.7% | -86.0% |
| Sep 2025 | NT$197.6 million | +18.4% | +790.2% |
| Aug 2025 | NT$22.2 million | -14.7% | -0.7% |
| Jul 2025 | NT$22.4 million | -11.9% | -85.5% |
| Jun 2025 | NT$153.7 million | -0.2% | +729.3% |
| May 2025 | NT$18.5 million | -78.6% | -24.4% |
| Apr 2025 | NT$24.5 million | +16.2% | -83.2% |
| Mar 2025 | NT$145.8 million | +22.6% | +701.5% |
| Feb 2025 | NT$18.2 million | -2.8% | -22.3% |
| Jan 2025 | NT$23.4 million | -12.8% | -98.7% |
| Dec 2024 | NT$1.83 billion | +1,148.7% | +7,830.9% |
| Nov 2024 | NT$23.1 million | +8.9% | +4.5% |
| Oct 2024 | NT$22.1 million | +14.8% | -86.7% |
Jan–Oct 2026 cumulative: NT$787.8 million (+20.5% YoY)
Other Biotech & Medical companies
Compare with peers: PharmaEngine vs PEC / PharmaEngine vs Lotus Pharm / PharmaEngine vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16